Bio-Techne Executive and Leadership Team

James Hippel, the Executive Vice President & Chief Financial Officer at Bio-Techne, manages the global fiscal strategy and capital allocation for the organization. Overseeing the financial planning and analysis functions, the Executive Vice President & Chief Financial Officer ensures that the company maintains the liquidity required to fund ongoing research and development in bioactive reagents. This role involves communicating financial performance to stakeholders and the Board, providing transparency regarding the economic impact of the firm's diagnostic product lines. By optimizing the balance sheet, James Hippel supports the expansion of the company's market presence in the life sciences sector. The Executive Vice President & Chief Financial Officer drives cost-efficiency initiatives that allow for sustained investment in drug discovery technologies. Through rigorous financial oversight, Hippel secures the long-term stability of the enterprise, enabling the continued delivery of essential tools that assist scientific investigations into the nature and progress of specific diseases.

Will Geist, the President, Protein Sciences Segment at Bio-Techne, directs the strategic growth and product development for the protein-focused division of the company. Overseeing the production of high-quality bioactive reagents, the President, Protein Sciences Segment ensures that the portfolio meets the rigorous standards required for scientific investigations into biological processes. This role involves managing the commercialization of protein-based tools that assist researchers in understanding disease mechanisms. By driving market expansion in the protein sciences sector, Will Geist contributes to the overall mission of providing innovative solutions for drug discovery. The President, Protein Sciences Segment collaborates with technical teams to refine product offerings, ensuring that the firm maintains a competitive edge in the life sciences industry. Through the effective management of this segment, Geist supports the global research community by providing the essential components needed for accurate biological analysis and the advancement of clinical diagnostic capabilities.

Steve Crouse, the President, Diagnostics & Spatial Biology Segment at Bio-Techne, directs the commercial strategy and operational execution for the company's diagnostic and spatial biology product lines. Overseeing the development of tools that enable precise clinical testing, the President, Diagnostics & Spatial Biology Segment ensures that the firm provides accurate diagnostic solutions to the healthcare community. This role involves managing the integration of spatial biology technologies into the existing product portfolio to enhance the understanding of disease progression. By driving the adoption of these advanced diagnostic tools, Steve Crouse supports the company's commitment to improving patient outcomes through scientific innovation. The President, Diagnostics & Spatial Biology Segment collaborates with clinical partners to ensure that the diagnostic offerings meet the evolving needs of the medical field. Through the strategic management of this segment, Crouse facilitates the delivery of high-impact diagnostic products that assist in the accurate identification and treatment of complex diseases.

Laurie Gilman, the Vice President, Finance Operations & Chief of Staff at Bio-Techne, directs the integration of financial workflows with executive decision-making processes. Overseeing the operational efficiency of the finance department, the Vice President, Finance Operations & Chief of Staff ensures that resource allocation aligns with the broader corporate objectives of the life sciences firm. This role involves managing cross-functional initiatives that bridge the gap between administrative functions and strategic research goals. By streamlining internal reporting structures, Laurie Gilman optimizes the fiscal health of the organization. The Vice President, Finance Operations & Chief of Staff maintains rigorous oversight of operational budgets, facilitating the development of bioactive reagents and clinical diagnostic tools. Through meticulous coordination of internal projects, Gilman supports the company's mission to provide high-quality scientific solutions to the global research community while maintaining strict adherence to financial compliance standards.

Cheryl Bethune, the Senior Vice President - Chief Human Resources Officer at Bio-Techne, architects the talent acquisition and organizational development strategies necessary to support a global life sciences workforce. Overseeing the cultivation of a high-performance culture, the Senior Vice President - Chief Human Resources Officer drives initiatives that attract top-tier scientific talent to the organization. This leadership role involves designing comprehensive compensation frameworks and professional development programs that align with the company's commitment to innovation in drug discovery and clinical diagnostics. By fostering an inclusive environment, Cheryl Bethune ensures that the workforce remains agile and capable of meeting the evolving demands of the research community. The Senior Vice President - Chief Human Resources Officer collaborates with executive leadership to align human capital with long-term business growth. Bethune maintains a focus on employee engagement and retention, which directly impacts the ability of the firm to deliver consistent, high-quality diagnostic tools to global markets.

Gary Latham, the Vice President & Chief Technology Officer at Bio-Techne, directs the technological roadmap and innovation pipeline for the company's suite of research tools. Overseeing the development of advanced bioactive reagents, the Vice President & Chief Technology Officer ensures that the firm remains at the forefront of scientific discovery. This role involves bridging the gap between complex biological research needs and the engineering of scalable diagnostic solutions. By managing the technical infrastructure required for high-throughput screening, Gary Latham enables the company to provide accurate clinical tests to the global diagnostic community. The Vice President & Chief Technology Officer collaborates with research teams to translate scientific breakthroughs into commercial products that assist in drug discovery efforts. Through the implementation of cutting-edge laboratory technologies, Latham drives the evolution of the product portfolio, ensuring that the organization continues to provide the means for precise and reliable clinical diagnoses across international markets.

Matt Mehlbrech, the IT Chief Information Officer & Vice President at Bio-Techne, architects the digital infrastructure and data security frameworks that support the company's global operations. Overseeing the integration of enterprise software systems, the IT Chief Information Officer & Vice President ensures that research data remains secure and accessible for clinical diagnostic applications. This role involves managing the technological backbone that facilitates collaboration between international research teams and manufacturing facilities. By implementing robust cybersecurity protocols, Matt Mehlbrech protects the intellectual property essential to the firm's drug discovery efforts. The IT Chief Information Officer & Vice President drives digital transformation initiatives that improve operational efficiency and data-driven decision-making across the organization. Through the deployment of scalable cloud solutions, Mehlbrech supports the company's ability to deliver high-quality reagents and diagnostic tools to the global life sciences community, ensuring that the technological environment remains resilient against evolving digital threats.